Kite Phar­ma gets FDA to sign off on new Cal­i­for­nia-based vec­tor man­u­fac­tur­ing fa­cil­i­ty

Kite Phar­ma just got FDA ap­proval to kick off op­er­a­tions at a new man­u­fac­tur­ing cam­pus.

The can­cer-fo­cused, CAR-T cell ther­a­py play­er made the an­nounce­ment Mon­day, say­ing that the fed­er­al reg­u­la­to­ry agency gave the green light to Kite’s 100,000 square-foot, retro­vi­ral vec­tor man­u­fac­tur­ing fa­cil­i­ty in Ocean­side, CA.

Kite’s glob­al head of tech­ni­cal op­er­a­tions Chris Mc­Don­ald tells End­points News that the fa­cil­i­ty has been in the works for about four years, af­ter Kite teamed up with its par­ent com­pa­ny Gilead. Gilead ac­quired Kite Phar­ma for just shy of $12 bil­lion in 2017.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER